In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed at $30.42 in the last session, up 2.84% from day before closing price of $29.58. In other words, the price has increased by $2.84 from its previous closing price. On the day, 0.59 million shares were traded. CRNX stock price reached its highest trading level at $30.58 during the session, while it also had its lowest trading level at $29.43.
Ratios:
We take a closer look at CRNX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 23.04 and its Current Ratio is at 23.04. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on March 25, 2025, initiated with a Buy rating and assigned the stock a target price of $60.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 19 ’25 when Pizzuti Dana sold 2,515 shares for $34.20 per share. The transaction valued at 86,021 led to the insider holds 72,233 shares of the business.
Knight Jeff E. sold 7,162 shares of CRNX for $244,964 on Mar 19 ’25. The Chief Operating Officer now owns 87,491 shares after completing the transaction at $34.20 per share. On Mar 19 ’25, another insider, Betz Stephen F., who serves as the Chief Scientific Officer of the company, sold 5,770 shares for $34.20 each. As a result, the insider received 197,353 and left with 108,588 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 2830535168 and an Enterprise Value of 1528189568. Its current Enterprise Value per Revenue stands at 1470.827 whereas that against EBITDA is -4.547.
Stock Price History:
The Beta on a monthly basis for CRNX is 0.38, which has changed by -0.29206425 over the last 52 weeks, in comparison to a change of 0.0635103 over the same period for the S&P500. Over the past 52 weeks, CRNX has reached a high of $62.53, while it has fallen to a 52-week low of $24.10. The 50-Day Moving Average of the stock is -8.62%, while the 200-Day Moving Average is calculated to be -35.61%.
Shares Statistics:
According to the various share statistics, CRNX traded on average about 1.03M shares per day over the past 3-months and 1119490 shares per day over the past 10 days. A total of 92.93M shares are outstanding, with a floating share count of 86.54M. Insiders hold about 6.99% of the company’s shares, while institutions hold 104.67% stake in the company. Shares short for CRNX as of 1743379200 were 8538327 with a Short Ratio of 8.30, compared to 1740700800 on 8108504. Therefore, it implies a Short% of Shares Outstanding of 8538327 and a Short% of Float of 9.34.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
